National BioService, an RVC Biofund portfolio company and resident of Skolkovo Technopark, was admitted to the Sirius Innovative Science and Technology Center (Sirius ISTC). The company plans to create a Center for Preclinical and Translational Research on the Sirius ISTC site.
National BioService combines the competencies of a biobank and bioservice. The company develops innovative drugs and diagnostic systems in partnership with leading domestic pharmaceutical companies.
This work is impossible without creating technological infrastructure for biobanking, which ensures uniform standards for the collection, processing, transportation, storage and labeling of biomaterials. The services to be offered at the future Center for Preclinical and Translational Research will be available not only to Sirius ISTC residents, but also to Russian and foreign pharmaceutical and diagnostic companies.
National BioService (https://nbioservice.com/) is the first Russian multidisciplinary commercial research biobank. The company has been part of the RVC Biofund portfolio since 2013 and has been a resident of the Skolkovo Technopark since 2015. In 2018, the project received support under the National Technology Initiative's Healthnet roadmap.
National BioService works closely with more than 135 clinics in 30 regions of Russia and has its own laboratories in Moscow, St. Petersburg, Nizhny Novgorod, Sochi, and Samara. The company's partners are leading domestic and foreign companies: R-Pharm, Generium, Pharmstandard, Biocad, Pharmsynthez, Diagnostic Systems, Novartis, GSK, AstraZeneca, Roche and UCB.
The Sirius Innovative Science and Technology Center (https://intc-sirius.ru/) was created to unify and cultivate innovative scientific, educational, experimental, and technology development practices in order to effectively achieve interdisciplinary objectives in the priority areas identified under the Scientific and Technological Development Strategy of the Russian Federation.